An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients

• Status: Completed
• Trial end date: 2007-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to compare the treatment of esomeprazole 40 mg once daily and lansoprazole 30 mg once daily in controlling intragastric pH in Barrett's Esophagus patients

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Dexlansoprazole; Esomeprazole; Lansoprazole

Criteria

Inclusion Criteria:

• Documented history (within 2 yrs of histologically proven BE;

• Aged 18-70 (inclusive);

• Willing and able to comply with all study procedures

Exclusion Criteria:

• Signs of clinically significant GI bleeding within 3 days prior to randomization;

• History of gastric or esophageal surgery;

• Clinically significant illness within 2 weeks prior to first dose of study drug or during study